Skip to main content

New Drug Approvals - Pt. I - Milnacipran (Ixel/Savella)

An occasional series of posts with news and top level details on new FDA drug approvals. The series is a little retrospective at the moment, but it will not take much time to catch up for 2009.

First 'out of the gates' on 14th Jan this year is an 'old' compound, Milnacipran (Savella in the US) for the treatment of fibromyalgia syndrome. Milnacipran is an SNRI (Serotonin Norepinephrine Reuptake Inhibitor, and as such blocks the function of the norepinephrine transporter NET and the serotonin transporter SERT), like all compounds of this pharmacological class, the molecule is small (Molecular Weight of 246.4 g.mol-1 for Milnacipran itself, and 282.2 g.mol-1 for the HCl salt) is fully Rule-Of-Five compliant, has high aqueous solubility, and also has good oral absorption (85% bioavailable) and metabolism characteristics. (A plasma half-life of ca. 8 hours, a volume of distribution of 400L, low plasma protein binding at 13%. Excretion is renal (through the kidneys and urine) and excretion is primarily of the unchanged drug (55% unchanged). With a molecule like this, it should come as no surprise that it is delivered orally. Recommended dosage is 100mg (or ~354µmol, or ~177µmol of the pharmacologically active enantiomer, see below) per day, although dosing is phased from a low dose to 'full' dose over a week. Milnacipran is more potent at blocking norepinephrine uptake than serotonin uptake. The full prescribing information is here.

Milnacipran has a boxed warning (colloquially known as a 'black box').

Notable features of the chemical structure ((±)-[1R(S),2S(R)]-2-(aminomethyl)-N,N-diethyl-1- phenylcyclopropanecarboxamide hydrochloride) are the primary amine (the NH2) which is basic (it can be protonated and therefore positively charged), which will dominate its physicochemical properties. The remainder of the molecule is quite lipophillic. Of further note is the cyclopropane ring (the triangle part in the middle), which is completely rigid and will dominate the three-dimensional properties (shape) of the drug. The functional groups attached to the cyclopropane are attached with mixed stereochemistry, so the drug is 'racemic' - for this reason stereochemistry is not explicitly shown on the the 2-D structure below. However, the stereoisomers have different pharmacological activity, with the 'active' d-isomer having different properties (e.g. a longer half-life) to the 'inactive' l-isomer Finally, the approved drug is not Milnacipran itself, but the Hydrochloride salt (so in the tablet the amine is indeed protonated, as discussed above).

Milnacipran canonical SMILES: CCN(CC)C(=O)C1(CC1CN)C2=CC=CC=C2 Milnacipran InChI: InChI=1S/C15H22N2O/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12/h5-9,13H,3-4,10-11,16H2,1-2H3 Milnacipran InChIKey: GJJFMKBJSRMPLA-UHFFFAOYSA-N Milnacipran HCl CAS registry: 101152-94-7 Milnacipran CAS registry: 92623-85-3 Milnacipran (two enantiomers) Chemdraw: Milnacipran.cdx

I mentioned it was an old compound, well it is, just that old is relative. The SNRI/SSRI therapeutic classes are old ones, and several drugs of these related classes are now available generically. SSRIs and SNRIs are primarily 'antidepressant' drugs, and this compound itself has been used in certain countries for some time (Austria, since 1998, and also at least Chile and Israel), there has been much interest in expanding the clinical use of SSRIs/SNRIs beyond their original antidepressant actions. As one would expect, the commercial history of Milnacipran appears quite complicated, and the latest approval is for a 'new' therapeutic indication - fibromyalgia (chronic and widespread muscle pain). Fibromyalgia is a complicated disease with several competing theories for its causes, and is often associated/comorbid with depression.

The license holder for Milnacipran is Cypress Bioscience and the product website is www.savella.com

Finally, given the age of the compound, it would be interesting to know what the patent status of the compound is?

Comments

Popular posts from this blog

New SureChEMBL announcement

(Generated with DALL-E 3 ∙ 30 October 2023 at 1:48 pm) We have some very exciting news to report: the new SureChEMBL is now available! Hooray! What is SureChEMBL, you may ask. Good question! In our portfolio of chemical biology services, alongside our established database of bioactivity data for drug-like molecules ChEMBL , our dictionary of annotated small molecule entities ChEBI , and our compound cross-referencing system UniChem , we also deliver a database of annotated patents! Almost 10 years ago , EMBL-EBI acquired the SureChem system of chemically annotated patents and made this freely accessible in the public domain as SureChEMBL. Since then, our team has continued to maintain and deliver SureChEMBL. However, this has become increasingly challenging due to the complexities of the underlying codebase. We were awarded a Wellcome Trust grant in 2021 to completely overhaul SureChEMBL, with a new UI, backend infrastructure, and new f

A python client for accessing ChEMBL web services

Motivation The CheMBL Web Services provide simple reliable programmatic access to the data stored in ChEMBL database. RESTful API approaches are quite easy to master in most languages but still require writing a few lines of code. Additionally, it can be a challenging task to write a nontrivial application using REST without any examples. These factors were the motivation for us to write a small client library for accessing web services from Python. Why Python? We choose this language because Python has become extremely popular (and still growing in use) in scientific applications; there are several Open Source chemical toolkits available in this language, and so the wealth of ChEMBL resources and functionality of those toolkits can be easily combined. Moreover, Python is a very web-friendly language and we wanted to show how easy complex resource acquisition can be expressed in Python. Reinventing the wheel? There are already some libraries providing access to ChEMBL d

LSH-based similarity search in MongoDB is faster than postgres cartridge.

TL;DR: In his excellent blog post , Matt Swain described the implementation of compound similarity searches in MongoDB . Unfortunately, Matt's approach had suboptimal ( polynomial ) time complexity with respect to decreasing similarity thresholds, which renders unsuitable for production environments. In this article, we improve on the method by enhancing it with Locality Sensitive Hashing algorithm, which significantly reduces query time and outperforms RDKit PostgreSQL cartridge . myChEMBL 21 - NoSQL edition    Given that NoSQL technologies applied to computational chemistry and cheminformatics are gaining traction and popularity, we decided to include a taster in future myChEMBL releases. Two especially appealing technologies are Neo4j and MongoDB . The former is a graph database and the latter is a BSON document storage. We would like to provide IPython notebook -based tutorials explaining how to use this software to deal with common cheminformatics p

Multi-task neural network on ChEMBL with PyTorch 1.0 and RDKit

  Update: KNIME protocol with the model available thanks to Greg Landrum. Update: New code to train the model and ONNX exported trained models available in github . The use and application of multi-task neural networks is growing rapidly in cheminformatics and drug discovery. Examples can be found in the following publications: - Deep Learning as an Opportunity in VirtualScreening - Massively Multitask Networks for Drug Discovery - Beyond the hype: deep neural networks outperform established methods using a ChEMBL bioactivity benchmark set But what is a multi-task neural network? In short, it's a kind of neural network architecture that can optimise multiple classification/regression problems at the same time while taking advantage of their shared description. This blogpost gives a great overview of their architecture. All networks in references above implement the hard parameter sharing approach. So, having a set of activities relating targets and molecules we can tra

ChEMBL 26 Released

We are pleased to announce the release of ChEMBL_26 This version of the database, prepared on 10/01/2020 contains: 2,425,876 compound records 1,950,765 compounds (of which 1,940,733 have mol files) 15,996,368 activities 1,221,311 assays 13,377 targets 76,076 documents You can query the ChEMBL 26 data online via the ChEMBL Interface and you can also download the data from the ChEMBL FTP site . Please see ChEMBL_26 release notes for full details of all changes in this release. Changes since the last release: * Deposited Data Sets: CO-ADD antimicrobial screening data: Two new data sets have been included from the Community for Open Access Drug Discovery (CO-ADD). These data sets are screening of the NIH NCI Natural Product Set III in the CO-ADD assays (src_id = 40, Document ChEMBL_ID = CHEMBL4296183, DOI = 10.6019/CHEMBL4296183) and screening of the NIH NCI Diversity Set V in the CO-ADD assays (src_id = 40, Document ChEMBL_ID = CHEMBL4296182, DOI = 10.601